120 related articles for article (PubMed ID: 6713388)
1. Immunotherapy with biochemically dissociated fractions of Propionibacterium acnes in a murine ovarian cancer model.
Berek JS; Cantrell JL; Lichtenstein AK; Hacker NF; Knox RM; Nieberg RK; Poth T; Elashoff RM; Lagasse LD; Zighelboim J
Cancer Res; 1984 May; 44(5):1871-5. PubMed ID: 6713388
[TBL] [Abstract][Full Text] [Related]
2. Synergistic effects of combination sequential immunotherapies in a murine ovarian cancer model.
Berek JS; Lichtenstein AK; Knox RM; Jung TS; Rose TP; Cantrell JL; Zighelboim J
Cancer Res; 1985 Sep; 45(9):4215-8. PubMed ID: 4028011
[TBL] [Abstract][Full Text] [Related]
3. Requirements for successful immunotherapy and chemoimmunotherapy of a murine model of ovarian cancer.
Vanhaelen CP; Fisher RI
Cancer Res; 1981 Mar; 41(3):980-3. PubMed ID: 7193085
[TBL] [Abstract][Full Text] [Related]
4. Role of inflammatory neutrophils in antitumor effects induced by intraperitoneal administration of Corynebacterium parvum in mice.
Lichtenstein AK; Berek J; Kahle J; Zighelboim J
Cancer Res; 1984 Nov; 44(11):5118-23. PubMed ID: 6488171
[TBL] [Abstract][Full Text] [Related]
5. Antitumor activity of Propionibacterium acnes (Corynebacterium parvum) and isolated cytoplasmic fractions.
Millman I; Scott AW; Halbherr T
Cancer Res; 1977 Nov; 37(11):4150-5. PubMed ID: 409491
[TBL] [Abstract][Full Text] [Related]
6. Successful immunotherapy with intraperitoneal Corynebacterium parvum in a murine ovarian cancer model is associated with the recruitment of tumor-lytic neutrophils into the peritoneal cavity.
Lichtenstein AK; Kahle J; Berek J; Zighelboim J
J Immunol; 1984 Jul; 133(1):519-26. PubMed ID: 6373934
[TBL] [Abstract][Full Text] [Related]
7. Antitumor and immunologic effects of a pyridine-extracted fraction of Propionibacterium acnes.
Lichtenstein A; Berek J
Cancer Immunol Immunother; 1986; 22(1):24-30. PubMed ID: 3708631
[TBL] [Abstract][Full Text] [Related]
8. Combination of transforming growth factor beta antisense and interleukin-2 gene therapy in the murine ovarian teratoma model.
Dorigo O; Shawler DL; Royston I; Sobol RE; Berek JS; Fakhrai H
Gynecol Oncol; 1998 Nov; 71(2):204-10. PubMed ID: 9826461
[TBL] [Abstract][Full Text] [Related]
9. Role of novel adjuvants in specific active immunotherapy.
Cantrell JL; Finn DJ
Prog Clin Biol Res; 1989; 288():297-307. PubMed ID: 2717639
[No Abstract] [Full Text] [Related]
10. Action of three species of Propionibacteria (P. granulosum, P. acnes, P. avidum) on experimental tumor systems in mice.
Roszkowski W; Kobus M; Luczak M; Ko HL; Szmigielski S; Laskowska B; Pulverer G; Jeljaszewicz J
Zentralbl Bakteriol A; 1980 Mar; 246(3):405-14. PubMed ID: 6252722
[TBL] [Abstract][Full Text] [Related]
11. IL-2 plasmid therapy of murine ovarian carcinoma inhibits the growth of tumor ascites and alters its cytokine profile.
Horton HM; Dorigo O; Hernandez P; Anderson D; Berek JS; Parker SE
J Immunol; 1999 Dec; 163(12):6378-85. PubMed ID: 10586027
[TBL] [Abstract][Full Text] [Related]
12. Immunotherapy of a murine ovarian carcinoma with Corynebacterium parvum and specific heteroantiserum. I. Activation of peritoneal cells to mediate antibody-dependent cytotoxicity.
Bast RC; Knapp RC; Mitchell AK; Thurston JG; Tucker RW; Schlossman SF
J Immunol; 1979 Nov; 123(5):1945-51. PubMed ID: 489967
[TBL] [Abstract][Full Text] [Related]
13. Efficient inhibition of intraperitoneal human ovarian cancer growth and prolonged survival by gene transfer of vesicular stomatitis virus matrix protein in nude mice.
Lin X; Chen X; Wei Y; Zhao J; Fan L; Wen Y; Wu H; Zhao X
Gynecol Oncol; 2007 Mar; 104(3):540-6. PubMed ID: 17112567
[TBL] [Abstract][Full Text] [Related]
14. Recombinant adeno-associated virus 2-mediated antiangiogenic prevention in a mouse model of intraperitoneal ovarian cancer.
Isayeva T; Ren C; Ponnazhagan S
Clin Cancer Res; 2005 Feb; 11(3):1342-7. PubMed ID: 15709207
[TBL] [Abstract][Full Text] [Related]
15. Effects of different fractions of Corynebacterium parvum on the cytotoxic T-cell response to alloantigens in mice.
Lichtenstein A; Tuttle R; Cantrell J; Zighelboim J
J Natl Cancer Inst; 1982 Aug; 69(2):495-501. PubMed ID: 6213807
[TBL] [Abstract][Full Text] [Related]
16. Rejection of murine ovarian cancer following treatment with regional immunotherapy: correlations with a neutrophil-mediated activation of cytostatic macrophages.
Lichtenstein A
Cell Immunol; 1985 Sep; 94(2):521-35. PubMed ID: 4028167
[TBL] [Abstract][Full Text] [Related]
17. [Construction of autocatalytic caspase-3 driven by amplified human telomerase reverse transcriptase promoter and its enhanced efficacy of inducing apoptosis in human ovarian carcinoma].
Song Y; Shen K; He CX
Zhonghua Fu Chan Ke Za Zhi; 2007 Sep; 42(9):617-22. PubMed ID: 17983518
[TBL] [Abstract][Full Text] [Related]
18. [The efficacy of autocatalytic casapse-3 driven by human telomerase reverse transcriptase promoter on human ovarian carcinoma].
Song Y; Shen K; Yu JR
Zhonghua Yi Xue Za Zhi; 2007 Nov; 87(41):2919-24. PubMed ID: 18261307
[TBL] [Abstract][Full Text] [Related]
19. Final report on the safety assessment of capsicum annuum extract, capsicum annuum fruit extract, capsicum annuum resin, capsicum annuum fruit powder, capsicum frutescens fruit, capsicum frutescens fruit extract, capsicum frutescens resin, and capsaicin.
Int J Toxicol; 2007; 26 Suppl 1():3-106. PubMed ID: 17365137
[TBL] [Abstract][Full Text] [Related]
20. Eradication of ovarian tumor xenografts by locoregional administration of targeted immunotherapy.
De Cesare M; Calcaterra C; Pratesi G; Gatti L; Zunino F; Mènard S; Balsari A
Clin Cancer Res; 2008 Sep; 14(17):5512-8. PubMed ID: 18765543
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
